Schizophrenia
A chronic, severe mental disorder characterized by hallucinations, delusions, disorganized thinking, and emotional flattening, causing severe functional impairment.
Emergency Management: Neuroleptic Malignant Syndrome (NMS): A life-threatening idiosyncratic reaction to antipsychotics. Stop the drug immediately, administer IV fluids, Bromocriptine (dopamine agonist), and Dantrolene for muscle relaxation. ICU admission required.
Schizophrenia is a severe, chronic psychiatric disorder characterized by a disintegration of thought processes, perception, and emotional responsiveness. It clinically manifests as a constellation of positive symptoms (hallucinations, delusions), negative symptoms (avolition, flat affect), and severe cognitive impairment lasting for at least 6 months.
Detailed Overview
Schizophrenia severely impairs occupational and social functioning. The exact etiology is unknown, but the neurodevelopmental hypothesis suggests that disrupted brain development during early life, combined with genetic vulnerability and environmental stressors (two-hit hypothesis), leads to profound neurotransmitter dysregulation, primarily involving dopamine and glutamate pathways. Patients often lack insight into their illness (anosognosia), leading to poor treatment adherence. Lifespan is significantly reduced due to high rates of suicide and severe metabolic comorbidities exacerbated by antipsychotic medications.
Epidemiology & Demographics
Lifetime prevalence is approximately 1% globally. Peak age of onset is late adolescence to early adulthood (18-25 years for males; 25-35 years for females). Females often have a second peak in their 40s.
Etiological Mechanism
A complex interplay of genetics (polygenic inheritance involving genes like COMT, dysbindin, and C4 complement genes) and environmental factors (obstetric complications, maternal infection during pregnancy, early childhood trauma, and adolescent cannabis use).
Primary Causes
Genetic Vulnerability
Neurodevelopmental Disruption
Environmental Stressors (Cannabis use in adolescence)
The dopamine hypothesis posits that positive symptoms are caused by dopaminergic hyperactivity in the mesolimbic pathway (VTA to nucleus accumbens), while negative and cognitive symptoms result from dopaminergic hypoactivity in the mesocortical pathway (VTA to prefrontal cortex). The glutamate hypothesis suggests NMDA receptor hypofunction on cortical GABAergic interneurons leads to downstream disinhibition of excitatory pathways, contributing to both symptom clusters. Structural neuroimaging consistently shows enlarged lateral ventricles and cortical thinning, particularly in the superior temporal gyrus and prefrontal cortex, indicating progressive gray matter loss.
Diagnostic Criteria & Guidelines
DSM-5 specifies: >= 2 core symptoms (delusions, hallucinations, disorganized speech, disorganized behavior, negative symptoms) present for a significant portion of a 1-month period. At least one must be delusions, hallucinations, or disorganized speech. Continuous signs of disturbance must persist for >= 6 months.
Second-Generation Antipsychotics (SGAs) are preferred to target positive symptoms with fewer extrapyramidal side effects. Risperidone 2-6 mg PO daily, Olanzapine 10-20 mg PO daily, or Aripiprazole 10-30 mg PO daily. Treatment must be combined with Cognitive Behavioral Therapy for Psychosis (CBTp) and supported employment.
Second-Line & Adjunctive Therapy
For Treatment-Resistant Schizophrenia (failure of >= 2 adequate antipsychotic trials): Clozapine 300-600 mg PO daily. Clozapine is the most effective antipsychotic but carries strict REMS monitoring requirements due to the risk of severe agranulocytosis. Long-Acting Injectables (LAIs) like Invega Sustenna (Paliperidone) are used for non-adherence.
Surgical & Procedural Management
Not applicable. Electroconvulsive Therapy (ECT) may be used for catatonia or severe refractory psychosis.
Patient Counseling & Advice
Counsel families that schizophrenia is a biological brain disease, not a moral failing. Emphasize that medication non-adherence is the primary cause of relapse, and each relapse causes further irreversible cognitive decline.
Follow-Up & Monitoring Schedule
Absolute Neutrophil Count (ANC) must be monitored weekly for the first 6 months if on Clozapine (ANC must be >= 1500/mcL). Monitor weight, BMI, BP, HbA1c, and lipid profile every 6 months for all SGAs. Assess for Tardive Dyskinesia using the AIMS scale annually.
Preventive Strategies
Early intervention in the prodromal phase (Clinical High Risk for Psychosis) with psychosocial support and omega-3 fatty acids may delay onset, but no definitive prevention exists.
Course is highly variable. ~20% have a favorable outcome and recover significantly; the majority have chronic relapsing courses with progressive functional decline. Life expectancy is reduced by 15-20 years.